Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins
Philosophical Transactions of the Royal Society B: Biological Sciences · 2024
DOI: 10.1098/rstb.2023.0234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Philosophical Transactions of the Royal Society B: Biological Sciences, 2024. Verfasst von Tomas Ondrejcak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, School of Medicine, and Institute of Neuroscience, Trinity College , Dublin 2, Republic of Ireland. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Brain, Long-Term Potentiation, tau Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, National Natural Science Foundation of China.
Abstract (Originalsprache)
How the two pathognomonic proteins of Alzheimer’s disease (AD); amyloid ß (Aß) and tau, cause synaptic failure remains enigmatic. Certain synthetic and recombinant forms of these proteins are known to act concurrently to acutely inhibit long-term potentiation (LTP). Here, we examined the effect of early amyloidosis on the acute disruptive action of synaptotoxic tau prepared from recombinant protein and tau in patient-derived aqueous brain extracts. We also explored the persistence of the inhibition of LTP by different synaptotoxic tau preparations. A single intracerebral injection of aggregates of recombinant human tau that had been prepared by either sonication of fibrils (SτAs) or disulfide bond formation (oTau) rapidly and persistently inhibited LTP in rat hippocampus. The threshold for the acute inhibitory effect of oTau was lowered in amyloid precursor protein (APP)-transgenic rats. A single injection of synaptotoxic tau-containing AD or Pick’s disease brain extracts also inhibited LTP, for over two weeks. Remarkably, the persistent disruption of synaptic plasticity by patient-derived brain tau was rapidly reversed by a single intracerebral injection of different anti-tau monoclonal antibodies, including one directed to a specific human tau amino acid sequence. We conclude that patient-derived LTP-disrupting tau species persist in the brain for weeks, maintaining their neuroactivity often in concert with Aß. This article is part of a discussion meeting issue ‘Long-term potentiation: 50 years on’.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, School of Medicine, and Institute of Neuroscience, Trinity College , Dublin 2, Republic of Ireland.
- Department of Physiology and Neurobiology, School of Basic Medical Sciences, Zhengzhou University, 100 Science Avenue , Zhengzhou 450001, People's Republic of China.
- School of Physics and Conway Institute of Biomolecular and Biomedical Research, University College Dublin , Dublin 4, Republic of Ireland.
ORCID-Profile: Michael J Rowan
Förderung
- Science Foundation Ireland
- National Natural Science Foundation of China
Zitieren
APA
Ondrejcak, T., Klyubin, I., Hu, N. W., Yang, Y., Zhang, Q., Rodriguez, B. J., & Rowan, M. J. (2024). Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins. Philosophical Transactions of the Royal Society B: Biological Sciences. https://doi.org/10.1098/rstb.2023.0234
Vancouver
Ondrejcak T, Klyubin I, Hu NW, Yang Y, Zhang Q, Rodriguez BJ, et al. Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins. Philosophical Transactions of the Royal Society B: Biological Sciences. 2024. doi:10.1098/rstb.2023.0234
BibTeX
@article{Ondrejcak2024,
author = {Ondrejcak, Tomas and Klyubin, Igor and Hu, Neng-Wei and Yang, Yin and Zhang, Qiancheng and Rodriguez, Brian J and Rowan, Michael J},
title = {Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins},
journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
year = {2024},
doi = {10.1098/rstb.2023.0234}
}
EUVIMED